Recent Updates — JAGX
Jaguar Health declared a special one-time stock dividend of one share of Series R Convertible Preferred Stock for each outstanding share of Common Stock and certain warrants, with a record date of October 13, 2026. Each preferred share converts into five shares of common stock on November 2, 2026, potentially issuing up to 11.4 million additional common shares. The company also amended royalty agreements with Uptown Capital and Streeterville Capital to extend monthly payment start dates to January 1, 2027, and extended the maturity date of a $6.2 million secured note to January 1, 2027. Jaguar Health is a commercial-stage pharmaceuticals company developing novel prescription medicines for gastrointestinal distress.
On September 25, 2026, Jaguar Health, Inc. entered into exchange agreements with Streeterville Capital, LLC to reduce the outstanding balance of its $6,220,812.50 secured promissory note by $3,400,000. In consideration for this debt reduction, the Company issued 481,584 shares of common stock to Streeterville. Following this transaction, the total number of shares outstanding was approximately 1,945,542. Jaguar Health, Inc. operates in the pharmaceutical industry, developing and commercializing treatments for gastrointestinal disorders.
Jaguar Health, Inc. entered into exchange agreements with Streeterville Capital, LLC to reduce its debt obligations by issuing common stock. The company issued 182,091 shares to reduce the outstanding balance of the 2021 Note by $1,678,320 and issued 547,898 shares to fully pay off and cancel the 2025 Note, reducing its balance by $5,049,909. Following these transactions, approximately 1,463,958 shares of common stock were issued and outstanding as of September 24, 2026. Jaguar Health operates in the pharmaceutical industry, developing treatments for gastrointestinal disorders.
On September 23, 2026, Jaguar Health, Inc. entered into exchange agreements with Streeterville Capital, LLC to reduce the outstanding balance of its $10,810,000 secured promissory note by $5,049,909.26. In consideration for this debt reduction, the Company issued 547,898 shares of common stock to Streeterville. Following this transaction, the total number of shares outstanding was approximately 1,281,867. Jaguar Health operates in the pharmaceutical industry, developing and commercializing treatments for gastrointestinal disorders.
Jaguar Health, Inc. filed a Certificate of Elimination with the Delaware Secretary of State on September 15, 2026, removing Series B-2 through O preferred stock from its authorized capital as all such shares had previously been converted or disposed of. The company also announced that it effected a one-for-fifteen reverse stock split of its common stock effective September 17, 2026, resulting in approximately 520,088 outstanding shares post-split. Jaguar Health operates in the pharmaceutical industry.
Jaguar Health executed multiple equity transactions in mid-September 2026 to raise capital and consolidate ownership of its Italian subsidiary, Napo Therapeutics. On September 11, the company exchanged a $175,016.36 convertible promissory note held by Lincoln Alternative Strategies for 557,377 shares of common stock. Simultaneously, it converted Series Q Preferred Stock held by Streeterville Capital into 304,473 total common shares across three agreements dated July 7, September 11, and September 14. Additionally, on September 12, Jaguar Health entered a securities purchase agreement to acquire the remaining minority stake in Napo Therapeutics from a related party by issuing 535,000 common shares and a pre-funded warrant for 2,077,255 shares; this transaction closed on September 15. These actions represent significant unregistered equity issuances and strategic consolidation of its pharmaceutical subsidiary.